Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) and Axcella Health (NASDAQ:AXLA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Taysha Gene Therapies and Axcella Health, as reported by MarketBeat.com.
Get Taysha Gene Therapies alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Taysha Gene Therapies | 0 | 0 | 11 | 0 | 3.00 |
| Axcella Health | 0 | 1 | 5 | 0 | 2.83 |
Taysha Gene Therapies currently has a consensus target price of $26.00, indicating a potential upside of 658.02%. Axcella Health has a consensus target price of $6.50, indicating a potential upside of 162.10%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Axcella Health.
Profitability
This table compares Taysha Gene Therapies and Axcella Health's net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Taysha Gene Therapies | N/A | -232.52% | -97.24% |
| Axcella Health | N/A | -253.31% | -113.66% |
Institutional & Insider Ownership
46.1% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 61.8% of Axcella Health shares are owned by institutional investors. 42.4% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 6.5% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Taysha Gene Therapies has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Earnings & Valuation
This table compares Taysha Gene Therapies and Axcella Health's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Taysha Gene Therapies | N/A | N/A | -$174.52 million | ($4.82) | -0.71 |
| Axcella Health | N/A | N/A | -$64.63 million | ($1.73) | -1.43 |
Axcella Health is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Summary
Taysha Gene Therapies beats Axcella Health on 7 of the 11 factors compared between the two stocks.
About Taysha Gene Therapies
(Get Rating)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
About Axcella Health
(Get Rating)
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.